Biomarkers in Metastatic Colorectal Cancer: Status Quo and Future Perspective.

Puccini, Alberto; Seeber, Andreas; Berger, Martin D (2022). Biomarkers in Metastatic Colorectal Cancer: Status Quo and Future Perspective. Cancers, 14(19) MDPI AG 10.3390/cancers14194828

Preview

Text cancers-14-04828.pdf - Published Version Available under License Creative Commons: Attribution (CC-BY). Download (468kB) | Preview

Colorectal cancer (CRC) is the third most frequent cancer worldwide, and its incidence is steadily increasing. During the last two decades, a tremendous improvement in outcome has been achieved, mainly due to the introduction of novel drugs, targeted treatment, immune checkpoint inhibitors (CPIs) and biomarker-driven patient selection. Moreover, progress in molecular diagnostics but also improvement in surgical techniques and local ablative treatments significantly contributed to this success. However, novel therapeutic approaches are needed to further improve outcome in patients diagnosed with metastatic CRC. Besides the established biomarkers for mCRC, such as microsatellite instability (MSI) or mismatch repair deficiency (dMMR), RAS/BRAF, sidedness and HER2 amplification, new biomarkers have to be identified to better select patients who derive the most benefit from a specific treatment. In this review, we provide an overview about therapeutic relevant and established biomarkers but also shed light on potential promising markers that may help us to better tailor therapy to the individual mCRC patient in the near future.

Interest & Impact

Downloads

59 since deposited on 17 Oct 2022
35 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item